Analysts’ Reports

RaaS Group has released its research report on Anatara Lifesciences (ASX:ANR) ahead of the ASX Small and Mid-Cap Conference 2020.

“Going with the gut”

Please open the attached PDF to view the report.

Pitt Street Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a $1.09/share base case and $3.20/share optimistic case valuation range.

“Detach upside remains”

Please open the attached PDF to view the report.

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report provided a SPEC BUY rating and a price target of $0.90 per share.

“Life after Zoetis”

Please open the attached PDF to view the report.

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.

“World IBD Day – Sunday 19 May – ANR offers natural treatment”

Please open the attached PDF to view the report.

Pitt Street Research Valuation Report – “Following the gut”

Pitt Street Research has released its follow-up research and valuation report on Anatara Lifesciences (ANR). The report valued Anatara at $1.34 base case and $3.61 optimistic case using a probability-weighted DCF valuation approach.

Please click on the PDF to view the report.

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.

“On track for GaRP supplement partner”

Please open the attached PDF to view the report.

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.

“Solid short term milestones”

Please open the attached PDF to view the report.

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.

“Restore human gut health with GaRP”

Please open the attached PDF to view the report.

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.55 per share.

“Zoetis wants global animal distribution for Detach®”

Please open the attached PDF to view the report.

This month PAC Partners initiated analyst coverage on Anatara Lifesciences.

PAC has initiated coverage with a Buy rating and price target of $1.36/share.

To download the full report, please click here.

NEW Wilsons Research & Valuation Report

Wilsons Equity Research has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.66 per share.

“Still have our nose in this little trough”

Please open the attached PDF to view the report.

NDF Research’s Initiation of Coverage Research & Valuation Report

NDF Research has released its first research and valuation report on Anatara Lifesciences (ANR). The report valued Anatara at $2.22 base case and $5.94 optimistic case using a DCF approach, with a target price of $4.00 sitting at around the midpoint of the valuation range.

Please click on the PDF to view the report.

Bioshares has featured Anatara Lifesciences (ANR) in its latest edition. The article provided a Speculative Buy Class B recommendation.

Bioshares delivers independent investment research to investors on Australian biotech, pharma and healthcare companies.

Please click here to view the article.

Wilson HTM has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and price target of $1.75 per share.

Please open the attached PDF to view the report.

Wilson HTM has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and a new price target of $1.75 per share.

Please open the attached PDF to view the report.

Wilson HTM has released its fourth research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and increased price target of $1.82 per share.

Please open the attached PDF to view the report.

Wilson HTM has released its third research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and a price target at $1.18 per share.

Please open the attached PDF to view the report.

Bioshares has featured Anatara Lifesciences (ANR) in its latest edition. The article provided a Speculative Buy recommendation.

Bioshares delivers independent investment research to investors on Australian biotech, pharma and healthcare companies.

Please open the attached PDF to view the report.

Wilson HTM has released its second research and valuation report on Anatara Lifesciences (ANR). The report provided a Speculative BUY rating and a price target at $1.18 per share.

Please open the attached PDF to view the report.

Bioshares has featured Anatara Lifesciences (ANR) in its latest edition. The article provided a Speculative Buy recommendation.

Please open the attached PDF to view the report.

Wilson HTM today released a research and valuation report on Anatara Lifesciences (ANR). The report initiated a Speculative BUY rating and a price target of 60 cps.

“Bull case valuations can push north of $2.50 per share if project success and international marketing partners are delivered over the next few years.”

Please open the attached PDF to view the report.